Physician profile
Deepak Sharma
NPI 1619430972
$1,358.66
in general payments reported to CMS, 2019-2025
19 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $31.42 · 2023: $635 · 2024: $452 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $332.84 | 2023-2025 | |
| Glaxosmithkline, LLC. | $206.52 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $132.76 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $126.67 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Procept Biorobotics Corporation | $119.04 | 2023 | Aquabeam Robotic System |
| Gilead Sciences, INC. | $61.13 | 2023-2024 | |
| Dexcom, INC. | $56.82 | 2023-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $49.77 | 2023-2025 | Mavyret |
| Otsuka America Pharmaceutical, INC. | $44.84 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $41.30 | 2022-2024 | Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $30.74 | 2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.60 | 2023 | Stiolto Respimat, Spiriva Respimat |
| Dynavax Technologies Corporation | $26.02 | 2024 | Heplisav-B |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.64 | 2025 | Caplyta |
| Smith+Nephew, INC. | $20.84 | 2023 | Regranex, Collagenase Santyl |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $15.58 | 2024 | Rexulti |
| Daiichi Sankyo INC. | $14.41 | 2024 | Injectafer |
| Exact Sciences Corporation | $13.67 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $13.47 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.